HK1064298B - Composition containing feverfew extract and use thereof - Google Patents

Description

Composition containing feverfew extract and its use

Technical Field

The present invention relates to compositions containing feverfeverfei (feverfew) extract and their use in cosmetics.

Background

It has been known for a long time in the middle ages that oral administration of Tanacetum parthenium, a plant commonly known as feverfew, has significant therapeutic efficacy as a general antipyretic, also its colloquial origin. Extracts have been isolated from this plant and used for oral treatment of migraine, arthritis and bronchial disorders. See, for example, U.S. patent 4,758,433 and PCT patent application No. WO 94/06800.

The extract of feverfew contains many components. Known feverfew fractions contain many biologically active components, although not all fractions are isolated and identified. Nowadays, the chemical components of the whole feverfew extract include, but are not limited to, apigenin-7-glucoside, apigenin-7-glucuronide, 1-beta-hydroxyarbusculin, 6-kaempferol-3, 7-4 ' -trimethy ether (Tanetin), 6-kaempferol-3, 7-dimethyl ether, 8-beta-reynosin, 10-epicannin, ascorbic acid, beta-carotene, calcium, chromium, wild chrysanthemum glycoside, chrysanthemomin, chrysaranten-A, chrysarten-C, chrysoeriol-7-glucuronide, cobalt, cosmosin, epoxyarteorin, luteolin-7-glucoside, luteolin-7-glucuronide, lignolide, parthenolide, quercetagetin-3, 7, 3 ' -trimethy ether, quercitrin-3 ' 7-dimethyl ether, reynosin, tanaparthin-1 alpha, 4 alpha-epoxide, tanaparthin-1 beta, 4 beta-epoxide, beta-costunolide, 3-beta-hydroxy-parthenolide, and 3,7, 3' -trimethoxyquercetagetin.

However, the specific role each component plays in the biological activity of feverfew is heretofore unknown. However, some information is known about the allergic reaction of such extracts. It is believed that most allergic reactions are caused by alpha-unsaturated gamma-lactones, such as parthenolide. See, for example, arch, dermotol, forsch, 1975, 251 (3): 235 to 44; arch, dermaltol, forsch, 1975, 255 (2): 111-21; contact Dermatitis, 1988, 38 (4): 207-8; am.J. contact Dermatol.1998-9 (1): 49-50; and br.j.cermatol, 1995, 132 (4): 543-47.

Although parthenolide has been reported to be effective in inhibiting photoaging of skin, see U.S. patent 6,130,254, there is no technical teaching to use a parthenolide extract with a reduced content of alpha-unsaturated gamma-lactone which causes allergy to modulate skin aging factors or to treat and prevent environmental damage or external invasion.

Summary of The Invention

In one aspect, the invention features a composition for regulating skin aging factors, such as skin firmness, tone, or texture, or regulating wrinkle production, the composition including a feverfew extract and a cosmetically acceptable vehicle. In one embodiment, the composition is substantially free of alpha-unsaturated gamma-lactones.

In another aspect, the invention features a composition for treating external aggressions in the skin, the composition comprising a feverfew extract and a cosmetically acceptable vehicle. In another aspect, the invention also features the use of the composition.

Other features and advantages of the invention will be apparent from the following claims.

Detailed Description

It is believed that one skilled in the art can, using the description herein, utilize the present invention to its fullest extent. The following specific embodiments are merely illustrative and should not be construed to limit the scope of the disclosure in any way.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. All percentages used herein are by weight unless otherwise indicated.

Definition of

As used herein, "topical application" means application directly on or to the external skin, for example, by hand or by an applicator such as a brush.

As used herein, "cosmetically acceptable" means an extract, cosmetically active agent, or inert ingredient suitable for use in contact with tissue (e.g., skin) that is not unduly toxic, incompatible, unstable, irritating, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.

As used herein, "regulating the firmness of the skin" means enhancing the firmness or elasticity of the skin, preventing the loss of firmness or elasticity of the skin, or preventing or treating skin laxity, and laxity. The firmness or elasticity of the skin can be measured with a cutometer. See Handbook of Non-Invasive Methods and the Skin, eds J.Serup and G.Kemec, Chapter 14.3 (1995). Loss of skin elasticity or firmness may be the result of a number of factors, including but not limited to aging, environmental damage, or the result of the application of cosmetics to the skin.

As used herein, "adjusting skin tone" refers to lightening and/or darkening skin color (e.g., lightening pigmented lesions or darkening darkened skin).

As used herein, "regulating the texture of the skin" refers to smoothing the skin surface to remove the ravines from the skin surface.

As used herein, "regulating skin wrinkles" means preventing, retarding, arresting or reversing the formation of wrinkles and fine lines in the skin.

As used herein, "treating external aggressions in the skin" refers to reducing or preventing damage to the skin from external aggressions. Examples of external aggressions include, but are not limited to, damage to the skin from the use of cleansers (e.g., topical cleansers containing surfactants), makeup, shaving, and environmental damage such as UV light (e.g., photodamage from sunlight or damage from natural light sources such as UV lamps and solar simulators), ozone, exhaust gases, pollution, chlorine and chlorine-containing compounds, and smoke. The effects of external invasion on the skin include, but are not limited to, oxidative and/or nitrosative damage to lipids, carbohydrates, peptides, proteins, nucleic acids, and vitamins, and modifications thereof. The effects of external invasion on the skin also include, but are not limited to, loss of cell viability, loss or alteration of cell function, and alteration of gene and/or protein expression.

As used herein, a "safe and effective amount" means an amount of a compound or composition (e.g., a feverfew extract) sufficient to provide a significant improvement in the condition to be conditioned or treated, but low enough to avoid serious side effects. The safe and effective amount of the compound or composition will vary depending upon the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the time of treatment, the nature of concurrent therapy, the particular compound or composition employed, the particular cosmetically acceptable topical carrier employed, and like factors.

Feverfew extract

By "feverfew extract" is meant a mixture of compounds isolated from a chrysanthemum or a plant of the genus tanacetum (hereinafter referred to as feverfew). Examples of feverfew include, but are not limited to, Chrysanthemum parthenium, tanacettum parthenium or Matricania parthenium, and CRC Ethnology Desk Reference1998, Timothy Johnson eds, 198-; http:// www.ipni.org [ visit 1/11 days 2001 ].

Such compounds can be isolated by physically pulling out a plant from a part(s) of the plant (e.g., the part of the plant that is in the air, such as the stem, flower, and leaves), such as by grinding the leaves of the plant. Extraction methods well known in the art may also be used (e.g., using organic solvents such as C)₁-C₈Alcohol, C₁-C₈Alkyl polyol, C₁-C₈Alkyl ketones, C₁-C₈Alkyl ethers, acetic acid C₁-C₈Alkyl esters and chloroform, and/or inorganicSolvents such as water, mineral acids such as hydrochloric acid, and inorganic bases such as sodium hydroxide) are separated from the plants. In one embodiment, the feverfew extract includes only hydrophilic compounds (e.g., isolated with a hydrophilic solvent such as water or alcohol). In another embodiment, the feverfew extract comprises only lipophilic compounds (e.g., isolated with a lipophilic solvent such as chloroform). In one embodiment, the feverfew extract includes both hydrophilic and lipophilic compounds.

In one embodiment, the feverfew extract is substantially free of alpha-unsaturated gamma-lactones. The term "substantially free of α -unsaturated γ -lactones" refers to a feverfew extract having a weight percent of α -unsaturated γ -lactones of less than about 0.2% by weight. These α -unsaturated γ -lactones include, but are not limited to, parthenolide, 3- β -hydroxy-parthenolide, costunolide, artemirin, 8- α -hydroxy-estafiatin, chrysanthemin, mangnoliolide, tanaparthin-1 α,4 α -epoxide, tanaparthin-1 β,4 β -epoxide, chrysanthemin, and other sesquiterpenes. Preferably, the weight percent of alpha-unsaturated gamma-lactones in the feverfew extract is less than about 0.02% by weight.

Alpha-unsaturated gamma-lactones, including parthenolide, are present in feverfew. A method of making a feverfew extract substantially free of parthenolide and other α -unsaturated γ -lactones is disclosed in PCT patent application No. 00/74695.

The amount of feverfew extract in the composition depends on the type of extract used. In one embodiment, the composition contains a safe and effective amount of the feverfew extract. The extract is typically included in the composition in an amount of about 0.001% to about 20% by weight, and particularly in an amount of about 0.01% to about 1% by weight.

The feverfew extract may contain the following: flavanoids/flavonoids including, but not limited to, tanetin, 3,7, 3' -trimethoxyquercetol, apigenin and derivatives thereof. When flavan/flavone compounds are present, they are present at a concentration of about 0.001% to about 0.5%, such as about 0.005% to 0.2%, based on the amount of the topical composition.

Topical compositions

Topical compositions useful in the present invention include formulations suitable for topical application to the skin. In one embodiment, the composition includes a feverfew extract and a cosmetically acceptable topical carrier. In one embodiment, the cosmetically acceptable topical carrier comprises about 50% to about 99.99% of the composition (e.g., about 80% to about 95% by weight of the composition).

In one embodiment, the composition is substantially free of parthenolide. This means that "substantially free of parthenolide" is that the composition contains less than 0.1%, preferably less than 0.01%, most preferably less than 0.001% by weight of parthenolide, or does not contain any parthenolide. In one embodiment, the composition is free of parthenolide.

The compositions can be formulated into a number of product types including, but not limited to, lotions, creams, gelling agents, sticks, sprays, shaving creams, ointments, liquid lotions and solid sticks, shampoos, pastes, powders, mousses, shaving creams, liniments, patches (batch), nail varnishes, wound dressings and adhesive bandages, hydrogels, films and cosmetics such as foundations, mascaras and lipsticks. These product types may include several cosmetically acceptable topical carriers including, but not limited to, solutions, emulsions (e.g., microemulsions and nanoemulsions), gels, liquids and solids, and liposomes. The following are non-limiting examples of such specific vectors. Other specific vectors can also be made by one of ordinary skill in the art.

Topical compositions useful in the present invention can be formulated as solutions. The solution typically includes an aqueous solvent (e.g., containing from about 50% to 99.99% or from about 90% to 99% of a cosmetically acceptable aqueous solvent).

Topical compositions useful for the purposes of the present invention may be formulated as solutions containing emollients. Such compositions preferably contain from about 2% to about 50% of an emollient. As used herein, "emollient" refers to a substance used to prevent or reduce dryness, as well as to protect the skin. Many suitable emollients are known and may be used herein. There are many examples of suitable substances in Sagarin, Cosmetics, Science and Technology, second edition, Vol.1, pp.32-43 (1972) and International Cosmetic Ingredient Dictionary and Handbook, Wenninger and McEwen eds., pp.1656-61, 1626 and 1654-55 (The Cosmetic Toiletry, and France Association, Washington D.C., 7 th edition, 1997) (hereinafter "ICI Manual").

With this solution, a washing liquid can be produced. Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.

Another type of product that can be made from a solution is a cream. A cream typically contains from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient and from about 45% to about 85% (e.g., from about 50% to 75%) of water.

Another type of product that can be made from a solution is an ointment. Ointments may contain a simple animal or vegetable oil or semi-solid hydrocarbon as the base. Ointments typically contain from about 2% to about 10% of an emollient and from about 0.1% to about 2% of a thickening agent. A more complete disclosure of thickeners or viscosity increasing agents useful herein can be found in Sagarin, Cosmetics, Science and Technology, second edition, Vol.1, pp.72-73 (1972) and in the ICI Manual, pp.1693-1697.

Topical compositions effective in the present invention may be formulated as emulsions. If the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier will contain an emulsifier. The emulsifier may be nonionic, anionic or cationic. Suitable Emulsifiers are disclosed, for example, in U.S. Pat. No. 3,755,560, U.S. Pat. No. 4,421,769, McCutcheon's Detergents and Emulsifiers, North American edition, pp.317-.

Lotions and creams may be formulated as an emulsion. Typically such emulsions contain from about 0.5% to about 5% emulsifier. Such creams typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient; from about 20% to about 80% (e.g., from about 30% to about 70%) water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier.

Single emulsion skin care products of the oil-in-water and water-in-oil type, such as lotions and creams, are well known in the cosmetic arts and are useful in the present invention. Multiple emulsion compositions, such as oil-in-water-in-oil, as described in U.S. patent nos. 4,254,105 and 4,960,764, are also useful in the present invention. Typically, such single or multiple phase emulsions contain water, an emollient, and an emulsifier as essential ingredients.

The topical compositions of the present invention may also be formulated as a gel (e.g., a hydrogel employing a suitable gelling agent). Suitable gelling agents for hydrogels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (e.g., mineral oil) include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymers and hydrogenated ethylene/propylene/styrene copolymers. Such gels typically contain from about 0.1% to 5% by weight of such gelling agents.

The topical compositions of the present invention may also be formulated as a solid formulation (e.g., a wax-based stick, soap stick composition, powder or powder-containing wipe).

Liposomal formulations are also useful for the present invention. Examples of liposomes are unilamellar, multilamellar and multilamellar liposomes, which may or may not contain phospholipids. The method may be performed by first following the Mezei & Gulasekharam, "Liposomes-A Selective drug Delivery System for the topic Route of Administration; the method of Gel DosageForm ", journal of pharmaceuticals and Pharmacology, Vol.34 (1982), pp.473-474, mixes hesperetin with phospholipids such as dipalmitoylphosphatidylcholine, cholesterol and water, or modifications thereof to prepare such compositions. Suitable compositions for forming liposomes have epidermal lipids that can replace phospholipids. Such liposome formulations can then be incorporated into one of the above-mentioned vehicles (e.g., a gel or an oil-in-water emulsion) to produce liposome formulations. Pharmaceutical uses of other compositions and commonly used Liposomes are described in Mezei, M., "Liposomes as a Skin Drug Delivery System", Topics in pharmaceutical sciences (D.D. Breimer and P.Speiser eds.), Elsevier Science Publishers B.V., New York, N.Y., 1985, page 345-358, PCT patent application WO96/31194 and U.S. Pat. No. 5,260,065.

In addition to the above components, the topical compositions useful in the present invention may contain various other oil-soluble and/or water-soluble materials which are conventionally used in compositions for application to the skin, hair and nails at levels established in the art.

Other cosmetic active agents

In one embodiment, the topical composition further comprises other cosmetically active agents in addition to feverfew extract. By "cosmetic active agent" is meant a compound having a cosmetic or therapeutic effect on the skin, hair or nails, such as whitening agents (lightening agents), tanning agents (tanning agents) such as self-tanning agents (self-tanning agents), anti-acne agents, oil control agents, antimicrobial agents, anti-inflammatory agents, antifungal agents, antiparasitic agents, external analgesics, sunscreens, photoprotective agents, antioxidants, keratolytic agents, detergents/surfactants, humectants, nutrients, vitamins, activators (energy enhancers), antiperspirants, astringents, deodorants, hair removers, firming agents, exfoliants, and agents for conditioning the skin, hair or nails.

In one embodiment, the agent is selected from, but is not limited to, hydroxy acids, benzoyl peroxide, thioresorcinol, ascorbic acid, D-panthenol, hydroquinone, octyl methoxycinnamate (octyl methoxycinnamate), titanium dioxide, octyl salicylate, homosalate, avobenzone, polyphenols, carotenoids, radical scavengers, spin traps (spin traps), retinoids (such as retinol and retinyl palmitate), ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogens, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as cupric chloride, copper-containing peptides such as Cu: gly-Hos-Lys, coenzyme Q10, peptides such as those disclosed in PCT patent application WO00/15188, lipoic acid, amino acids such as proline and tyrosine, alpha-hydroxy acids, alpha-hydroxy, Vitamins, lactobionic acid, acetyl-coa, niacin, flavins, thiamine, ribose, electron transfer agents such as NADH and FADH2, and other plant extracts such as aloe vera (aloe vera) and soy, and derivatives and mixtures thereof. The cosmetically active agent is typically present in the compositions of this invention in an amount of about 0.001% to about 20% by weight, such as about 0.01% to about 10%, for example about 0.1% to about 5%.

Examples of vitamins include, but are not limited to, vitamin a, vitamin B species such as vitamin B3, vitamin B5 and vitamin B12, vitamin C, vitamin K and vitamin E, and derivatives thereof.

Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid. See, for example, european patent application No. 273,202.

Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid, as well as ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide). Oil-soluble antioxidants suitable for use in the compositions of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (such as retinol and retinol palmitate), tocopherols (such as tocopheryl acetate), tocotrienols, and ubiquinone. Natural extracts containing antioxidants suitable for the compositions of the present invention include, but are not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (such as genistein and diadzein), extracts containing resveratrol and the like. Examples of such natural extracts include grape seed, green tea, pine bark and propolis. Further examples of antioxidants can be found on pages 1612-13 of the ICI handbook.

Other substances

Various other materials may also be included in the compositions useful in the present invention. These include humectants, proteins and polypeptides, preservatives, and alkaline agents. Examples of such agents are disclosed on pages 1650-1667 of the ICI handbook. The compositions of the present invention may also contain chelating agents (such as EDTA) and preservatives (such as parabens). Examples of suitable preservatives and chelating agents are listed on pages 1626 and 1654-55 of the ICI handbook. In addition, typical compositions useful herein may contain conventional cosmetic adjuvants such as dyes, opacifiers (e.g., titanium dioxide), pigments and fragrances.

Mineral water

The compositions of the present invention may be prepared with mineral water. In one embodiment, the mineral water is mineralized to at least about 200mg/L (e.g., from about 300mg/L to about 1000 mg/L). In one embodiment, the mineral water contains at least about 10mg/L calcium and/or at least about 5mg/L magnesium.

The compositions and formulations of the present invention containing such compositions may be prepared by methods well known to those of ordinary skill in the art.

Example 1: inhibition of UV-induced MMPs

The ability of feverfew extract to inhibit UV-induced matrix metalloproteinase-1 (MMP-1) was assessed in epidermal keratinocyte-derived epidermal equivalents in normal humans. MMPs are a class of enzymes that play a major role in the physiological remodeling and pathological destruction of the extracellular matrix. Sub-rubella (subrythamal) doses of UV light are known to cause secretion of MMPs in human skin, which in turn break down the extracellular matrix and play an important role in photoaging wrinkle formation and loss of firmness and elasticity. See g.j.fisher et al, Nature 379: 335-: 61-68(1998).

To evaluate the ability of feverfew extracts to inhibit UV-induced MMP-1, epidermal equivalents were obtained from SkinEthic (Nice, France) and cultured in medium without phenol, without hydrocortisone (SkinEthic). This equivalent is then topically treated with typically 0% or 0.5% by weight of feverfeverfew Extract (sold by Indena, s.p.a., Milan, Feverfew Dry Extract d.j. italy) for 1-2 hours, and then irradiated with a 1000 watt solar uv simulator (Oriel, Stratford, CT, USA) at doses of 0, 5, 7, 9 and 11MED with solar spectral light. After 48 hours of irradiation, the medium under each equivalent was collected and analyzed for secreted MMP-1 by ELISA (Calbiochem, san Diego, Calif., USA). The results of this experiment are listed in table 1.

TABLE 1

These results demonstrate that a formulation containing feverfew extract provides protection against MMP-1 formation after exposure to sunlight at doses up to 11 MED.

Example 2: preventing loss of mercaptans caused by smoke

The ability of feverfew extract to prevent smoke-induced thiol loss was assessed in normal human dermal fibroblasts (Clonetics, san Diego, Calif.). Thiols, mainly glutathione, are part of the endogenous antioxidant defense system of the cell. Thus, glutathione as a redox buffer can maintain the balance between the oxidant and the antioxidant. Glutathione is also a preferred substrate for certain enzymes such as glutathione peroxidase (catabolic enzyme) and glutathione-S-transferase (a major class of detoxification enzymes). See a. meister, Cancer res.54: 1969-.

Skin antioxidants (both enzymatic and non-enzymatic), including glutathione, are depleted after exposure to UV or ozone. See m.j.conner and l.a.wheeler, photochem.photobiol.46: 239-: 405-412(1988). In cell culture models, low intracellular Glutathione (GSH) levels result in higher sensitivity to UV irradiation. In general, the use of cysteine derivatives on rat skin has been shown to resist photodamage caused by UV radiation; this effect is associated with an increase in GSH synthesis. See l.t.van den Broeke and g.m.j.beijersbergen van henegouwen.j.photochem.photobiol.b.biol.27: 61-65 (1995); hanada et al, j. invest. dermaltol.108: 727-730 (1997); and d.p.t.steenvvoorden et al, pathotomphotoobiol.67: 651-656(1998). As a result, glutathione is a major endogenous antioxidant, highly responsive to environmental challenges, capable of regulating skin tone and wrinkling, and coping with external aggressions.

In this experiment, normal human neonatal dermal fibroblasts seeded in 24-well Transwell inserts (Corning Costar, cambriqi, ma) were cultured in medium containing various concentrations of feverfew extract for 24 hours and then exposed to placebo (mock) or cigarette smoke (1 cigarette, BASIC Full flavour 100 cigarette, Philip Morris, Richmond, VA) for 10 minutes. Prior to exposure to smoke, the medium containing the feverfew extract on the inserts was removed and the cells were washed 3 times with Dulbecco's phosphate buffered saline (Life Technologies, Gaithersburg, Md.), and then exposed to smoke, when only the inserts were under the medium. Immediately after exposure, the cells were further cultured for 24 hours with the foregoing medium, washed 5 times with Dulbecco's phosphate buffered saline, and 60. mu.M monobromobimane (Molecular Probes, Eugene, OR, USA) was added to the cells, incubated at 37 ℃ for 30 minutes and then read for fluorescence, thus measuring intracellular thiols. Monobromobimane fluoresces when thiols are present. By usingFluorescence plate reader (PerSeptive Biosystems, Framingham, MA, USA) measures thisFluorescence, provided with the following filter combination: excitation at 360nm and emission at 460 nm.

The results of this example are shown in Table 2.

TABLE 2

	Concentration of Feverfew extract (. mu.g/ml)	Mercaptans (percentage of mercaptans in the group without Smoke; mean. + -. standard deviation)
			Non-smoke	0	100±12.2
Smog (10 minutes)	011025	58.83±7.770.32±16.799.53±12.6103.5±4.8

These results demonstrate that feverfew extract prevents the loss of thiols by smoke (data representing the results of 8-9 replicates from 2 independent experiments).

It is to be understood that while the invention has been described in detail, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.

Claims (9)

1. Use of a feverfew extract in the manufacture of a composition for modulating skin aging factors and/or treating nucleic acid damage in skin, wherein the feverfew extract contains at least one compound selected from the group consisting of tanetin, 3,7, 3' -trimethoxyquercetol and apigenin, and the composition is substantially free of parthenolide.

2. The use of claim 1, wherein said composition is for enhancing skin firmness or elasticity.

3. The use according to claim 1, wherein the composition is for regulating skin tone.

4. The use of claim 1, wherein the composition is for delaying the development of wrinkles or fine lines in the skin.

5. The use of claim 1, wherein the composition is for treating nucleic acid lesions in skin.

6. The use of claim 1, wherein said composition comprises from 0.001%, by weight, to 20%, by weight, of said feverfew extract.

7. The use according to claim 1, wherein the composition further comprises retinol.

8. The use according to claim 1, wherein the composition further comprises green tea extract.

9. The use of claim 1, wherein the composition further comprises a soy extract.